cures [30:<1% (Limited to important or life-threatening): Angioedema, bronchospasm, choriodal detachment (following filtration procedures), dyspnea, epistaxis, myopia (transient), ocular pain, paresthesia, Stevens-Johnson syndrome, throat irritation, toxic epidermal necrolysis Warnings/Precautions Concerns related to adverse effects: Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis. Ocular effects: Local ocular adverse effects (primarily conjunctivitis and lid reactions) were reported with chronic administration; many resolved upon discontinuation of drug therapy. Choroidal detachment has been reported after filtration procedures. Sulfonamide ( sulfa ) allergy: Dorzolamide is a sulfonamide; although administered ocularly, systemic absorption may occur and could result in hypersensitivity. Discontinue use if signs of hypersensitivity or a serious reaction occur. Systemic effects: Systemic absorption and adverse effects (similar to sulfonamides) including, blood dyscrasias, Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias may occur with ophthalmic use. Disease-related concerns: Corneal endothelium: Use with caution in patients with low endothelial cell counts; may be at increased risk of corneal edema. Hepatic impairment: Use with caution in patients with hepatic impairment (has not been studied). Renal impairment: Use is not recommended in patients with severe renal impairment (CrCl> <30 mL/minute) (has not been studied). Concurrent drug therapy issues: Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed. Special populations: Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting. Other warnings/precautions: Appropriate use: Should be used in combination with therapeutic interventions for the treatment of acute angle-closure glaucoma. Monitoring Parameters Ophthalmic exams and IOP periodically Pregnancy Risk Factor C Pregnancy Considerations Adverse events have been observed in animal reproduction studies following systemic administration. IOP is usually lower during pregnancy. If topical medications for the treatment of glaucoma in pregnant women cannot be discontinued because small increases in IOP cannot be tolerated, the minimum effective dose should be used in combination with punctual occlusion to decrease exposure to the fetus (Johnson, 2001). Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience blurred vision, burning, stinging, bad taste, dry eyes, watery eyes, or sensitivity to lights. Have patient report immediately to prescriber vision changes, eye pain, severe eye irritation, edema of eye or eyelid, or signs of a severe sulfonamide reaction (rash; red, swollen, blistered, or peeling skin; red or irritated eyes; mouth, throat, nose, or eye sores; fever, chills, or pharyngitis; cough that is new or worse; loss of strength and energy; any bruising or bleeding; or signs of liver problems (dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or jaundice) (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients. Next Interactions Print this page Add to My Med List More about dorzolamide ophthalmic Side Effects During Pregnancy or Breastfeeding Dosage Information Drug Interactions Support Group Pricing & Coupons En Español 5 Reviews Add your own review/rating Drug class: ophthalmic glaucoma agents Consumer resources Dorzolamide ophthalmic Dorzolamide Dorzolamide Ophthalmic (Advanced Reading) Professional resources Dorzolamide Hydrochloride (AHFS Monograph) Dorzolamide (FDA) Other brands: Trusopt Related treatment guides Glaucoma, Open Angle Intraocular Hypertension> ] Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA WADA Class Anti-Doping Classification Dorzolamide ophthalmic Rating 5 User Reviews 7.4 /10 5 User Reviews 7.4 Rate it! Manufacturers Akorn, Inc. Sandoz Inc. Teva Pharmaceuticals USA, Inc. Alvogen, Inc. More... Drug Class Ophthalmic glaucoma agents Related Drugs ophthalmic glaucoma agents timolol ophthalmic , Lumigan , latanoprost ophthalmic , Travatan , brimonidine ophthalmic , Xalatan Intraocular Hypertension timolol ophthalmic , Lumigan , latanoprost ophthalmic , Travatan , brimonidine ophthalmic , Xalatan , Combigan , Alphagan , pilocarpine ophthalmic , Cosopt , Azopt , bimatoprost ophthalmic , More... Glaucoma, Open Angle timolol ophthalmic , Lumigan , latanoprost ophthalmic , Travatan , brimonidine ophthalmic , Xalatan , epinephrine ophthalmic , Alphagan , pilocarpine ophthalmic , Cosopt , Azopt , bimatoprost ophthalmic , More... surgery
shots Dorzolamide the jobs
EmoticonEmoticon